Profile
Corporate information
Registration country
Investment activity status
Active investor
Company type
AI-enabled SaaS that diagnoses drug-resistant turberculosis (DR-TB) in hours instead of weeks.Overview
AarogyaAI enables precision medicine for anti-microbial resistance in infectious disease by unlocking the power of genomics and artificial intelligence. Tuberculosis is the most lethal infectious disease, globally. Drug-resistant TB and its delayed diagnosis, exacerbate the problem. AarogyaAI’s drug susceptibility test ensures patients are prescribed the most effective drugs, 100X faster than the existing gold standard. The company is backed by the largest genomics company in the world, Illumina Inc. as part of the Illumina Accelerator Program at San Francisco, USA. The Minister of Health, Govt. of India, Startup India, BIRAC amongst others in the Indian Ecosystem have recognized and awarded the innovation.
Funding
Funding rounds
(31 Dec 2019)
Investor | Profile | Country | Notes | |
---|---|---|---|---|
![]() |
Entrepreneur First Investment Manager LLP | Tehnology incubator that invests in individuals “pre-team, pre-idea” to help create new technology startups. | United Kingdom | Initial investment. Round participant. |
Cap Table
Current and past shareholders
Investor | Round | |
---|---|---|
![]() |
Entrepreneur First Investment Manager LLP Tehnology incubator that invests in individuals “pre-team, pre-idea” to help create new technology startups. |
Seed |